The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; GlaxoSmithKline; Incyte; Inivata; Janssen; Lilly; MSD; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; GlaxoSmithKline; Janssen; Lilly; Merck Serono; MSD Oncology; Novartis; Peptomyc; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb; CME outfitters; Lilly; Medscape; Merck Sharp & Dohme; PeerVoice; Pfizer; Roche; Takeda
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRÍFOLS
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; Archer; ARIAD; AstraZeneca; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; EMD Serono; Foundation Medicine; Genentech; Gilead Sciences; Gritstone Bio; Hengrui Therapeutics; Instil Bio; Janssen Oncology; Maverick Therapeutics; Merck; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Panasonic; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)
 
Wei Wang
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Sung Jin Kim
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Maria Catherine Pietanza
Employment - Merck
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Delvys Rodriguez-Abreu
Consulting or Advisory Role - AstraZeneca Spain; Bristol-Myers Squibb; MSD; Novartis; Roche
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche